Rallybio Corporation RLYB

RLYB Company Overview

Rallybio Corporation is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. The company operates within the biotechnology and biopharmaceutical industries, with a strategic emphasis on immunology, hematology, maternal-fetal health, and rare genetic or metabolic disorders. Rallybio’s primary value drivers are its clinical development programs, intellectual property portfolio, and strategic collaborations aimed at advancing targeted therapies for underserved patient populations.

The company was formed in 2018 by a group of biotechnology and pharmaceutical executives with prior experience in rare disease drug development, including leadership backgrounds associated with Alexion Pharmaceuticals and other biotechnology firms. Rallybio has evolved from a multi-asset rare disease platform into a more focused clinical development organization centered on high-need indications with limited approved treatment options. Its positioning is based on concentrating resources on narrowly defined diseases where biologic therapies, precision medicine approaches, and orphan drug pathways may provide regulatory and commercial advantages.